The allergic person makes too much of a certain protein in the body, called IgE antibody. The overproduction of this protein may result in the development of various allergic conditions such as allergic rhinitis (hay fever), allergic asthma, venom sensitivity, food or drug allergy.
Xolair is a drug that acts by binding to the IgE antibody in the blood stream and hence neutralizes (blocking) its actions. The U.S. Food and Drug Administration (FDA) has approved Xolair for the treatment of patients with moderate to severe allergic asthma and chronic urticaria (hives).
Xolair is indicated for adults and adolescents (≥12 years of age) who have moderate to severe asthma that is not currently controlled with inhaled corticosteroids and are sensitive (allergic) to perennial (year-round) aeroallergens. For example: dust mites, animals, mold, cockroach and certain pollens. Xolair is also considered in patients ≥12 years of age with chronic hives.